Sumitomo Mitsui Trust Group Inc. Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Sumitomo Mitsui Trust Group Inc. increased its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 544,170 shares of the medical equipment provider's stock after acquiring an additional 15,820 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.24% of Hologic worth $39,229,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Choreo LLC increased its stake in shares of Hologic by 14.2% in the 4th quarter. Choreo LLC now owns 6,646 shares of the medical equipment provider's stock valued at $480,000 after acquiring an additional 825 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Hologic by 27.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,939 shares of the medical equipment provider's stock valued at $1,954,000 after purchasing an additional 5,825 shares in the last quarter. Yousif Capital Management LLC grew its stake in shares of Hologic by 0.6% in the 4th quarter. Yousif Capital Management LLC now owns 46,219 shares of the medical equipment provider's stock worth $3,332,000 after acquiring an additional 294 shares in the last quarter. E. Ohman J or Asset Management AB grew its stake in shares of Hologic by 25.9% in the 4th quarter. E. Ohman J or Asset Management AB now owns 10,200 shares of the medical equipment provider's stock worth $735,000 after acquiring an additional 2,100 shares in the last quarter. Finally, Mather Group LLC. grew its stake in shares of Hologic by 236.0% in the 4th quarter. Mather Group LLC. now owns 2,937 shares of the medical equipment provider's stock worth $212,000 after acquiring an additional 2,063 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HOLX. UBS Group upped their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Stephens reiterated an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Morgan Stanley reduced their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, Royal Bank of Canada cut their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a report on Thursday, February 6th. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $85.77.

Hologic Price Performance

Shares of HOLX traded down $0.38 during midday trading on Friday, hitting $63.24. 2,320,041 shares of the company traded hands, compared to its average volume of 2,537,918. The stock has a 50-day moving average of $71.04 and a 200-day moving average of $77.26. Hologic, Inc. has a one year low of $62.94 and a one year high of $84.67. The firm has a market cap of $14.19 billion, a P/E ratio of 19.95, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.